These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23053221)

  • 1. Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis.
    Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Arch Dermatol Res; 2013 Jan; 305(1):17-23. PubMed ID: 23053221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.
    Hasegawa M; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K
    Rheumatology (Oxford); 2013 Feb; 52(2):242-51. PubMed ID: 23024058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis.
    Yanaba K; Hayashi M; Yoshihara Y; Nakagawa H
    J Dermatol; 2016 Aug; 43(8):954-7. PubMed ID: 26945563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.
    Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2012 Sep; 22(5):668-75. PubMed ID: 22160844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease.
    Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Shimizu K; Sato S
    Int J Rheum Dis; 2013 Aug; 16(4):442-7. PubMed ID: 23992266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different contributions of angiostatin and endostatin in angiogenesis impairment in systemic sclerosis: a cohort study.
    Almeida I; Oliveira Gomes A; Lima M; Silva I; Vasconcelos C
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):37-42. PubMed ID: 26885625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C.
    Wang D; Zhou D; Du Q; Liang Q; Wang Q; Fang L; Wang G; Fan Q; Liu B; Zhou J; Tang Z; Wu H; Guo X; Jiao Y; Zhang G
    Mol Med Rep; 2013 Apr; 7(4):1197-202. PubMed ID: 23426717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
    Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of soluble inducible costimulator level and its polymorphisms on age-related macular degeneration.
    Yu H; Zou X; Peng L; Wang Y; Zhang C; Chen B; Zou Y
    DNA Cell Biol; 2013 Dec; 32(12):717-21. PubMed ID: 24083358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.
    Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2012 Aug; 22(4):576-83. PubMed ID: 22075605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
    Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
    Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
    Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis.
    Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Br J Dermatol; 2012 Sep; 167(3):542-7. PubMed ID: 22540233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant production of soluble inducible T cell co‑stimulator and soluble programmed cell death protein 1 in patients with chronic hepatitis B.
    Wang D; Du Q; Luo G; Wang Q; Wang G; Zhang G; Leng Z; Guo X
    Mol Med Rep; 2017 Dec; 16(6):8556-8562. PubMed ID: 28983583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease.
    Kuzumi A; Yoshizaki A; Toyama S; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Asano Y; Sato S
    J Dermatol; 2018 Oct; 45(10):1216-1220. PubMed ID: 30004593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage.
    Ogawa F; Shimizu K; Hara T; Muroi E; Hasegawa M; Takehara K; Sato S
    Clin Exp Rheumatol; 2008; 26(4):659-62. PubMed ID: 18799101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.